Current Report Filing (8-k)
June 03 2020 - 06:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 1, 2020
Iterum Therapeutics plc
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Ireland
|
|
001-38503
|
|
98-1283148
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
Block 2 Floor 3, Harcourt Centre,
Harcourt Street,
Dublin
2, Ireland
|
|
Not Applicable
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: +353 1 903 8920
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange
on Which Registered
|
Ordinary Shares, par value $0.01 per share
|
|
ITRM
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On June 1, 2020, the Company issued a press release announcing topline results for its Phase 3 clinical trial of oral and IV sulopenem in
complicated urinary tract infection, including that the clinical trial did not meet its primary endpoint, and that the Company is evaluating its corporate, strategic and financial alternatives.
The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Iterum Therapeutics plc
|
Dated: June 2, 2020
|
|
|
|
|
By:
|
|
/s/ Corey N. Fishman
|
|
|
|
|
Corey N. Fishman
|
|
|
|
|
Chief Executive Officer
|
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2023 to Mar 2024